<DOC>
	<DOCNO>NCT01864148</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy BIIB033 participant active relapse MS use concurrently Avonex . Secondary objective study study population ass safety , tolerability , population PK BIIB033 use concurrently Avonex</brief_summary>
	<brief_title>Study Assess Efficacy , Safety , Tolerability , Pharmacokinetics BIIB033 Participants With Relapsing Forms Multiple Sclerosis When Used Concurrently With Avonex</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) onset Secondary Progressive Multiple Sclerosis ( SPMS ) RRMS SPMS subject must evidence ongoing disease activity within 12 month enrollment . All male female subject childbearing potential must practice effective contraception study willing able continue contraception least 6 month last dose study treatment Key A Multiple Sclerosis ( MS ) relapse occur within 90 day prior Day 1/Baseline and/or subject stabilize previous relapse prior Screening Previous history clinically significant disease . Plans undergo elective major procedures/surgeries time study . Treatment investigational Multiple Sclerosis ( MS ) drug within 3 week 5 time half life ( whichever longer ) prior Day 1/Baseline Relapsing Remitting Multiple Sclerosis ( RRMS ) subject history inadequate response approve interferon Î² preparation History Human Immunodeficiency Virus ( HIV ) , hepatitis C virus antibody , hepatitis B virus History evidence drug alcohol abuse within 2 year prior Randomization Note : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>